Track ImmunityBio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ImmunityBio, Inc. IBRX · Stock Open ImmunityBio, Inc. in new tab

6.02 USD
EPS
-0.96
P/B
-6.79
Beta
0.17
Target Price
14.25 USD
Loading chart...
Key Metrics
Earnings dateMarch 2, 2027
EPS-0.96
Book Value-0.99
Price to Book-6.79
% Insiders62.155%
Growth
Revenue Growth0.52%
Estimates
Forward P/E-91.98
Forward EPS-0.07
Target Mean Price14.25

DCF valuation

Model fair value for ImmunityBio, Inc. (IBRX)
Result
Sign in to run the valuation for IBRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 14.25 USD (low 12.00, high 16.00) · as of 11 Nov 2026
Low 12.00
Mean 14.25
High 16.00
Price 6.02
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

ImmunityBio, Inc. Logo ImmunityBio, Inc. Analysis (IBRX)

United States Health Care Official Website Stock

Is ImmunityBio, Inc. a good investment? ImmunityBio, Inc. (IBRX) is currently trading at 6.02 USD. Market analysts have a consensus price target of 14.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: ImmunityBio, Inc. is expected to release its next earnings report on March 2, 2027. The market consensus estimate for Forward EPS is -0.07.

Investor FAQ

Does ImmunityBio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is ImmunityBio, Inc.?

ImmunityBio, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 2, 2027. The company currently has a trailing EPS of -0.96.

Company Profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Exchange Ticker
FRA (Germany) 26CA.F
NMS (United States) IBRX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion